Lakefront Biotherapeutics (LKFT) Net Cash Flow (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has 13 years of Net Cash Flow data on file, last reported at -$39.4 million in Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$39.4 million, down 191.85% year-over-year; the trailing twelve-month figure through Mar 2026 was $163.4 million (down 33.3% YoY), and the FY2025 annual result was $32.7 million, up 129.32% from the prior year.
• Net Cash Flow slipped to -$39.4 million in Q1 2026 per LKFT's latest filing, from $54.1 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $83.9 million in Q2 2025 and troughed at -$1.1 billion in Q1 2022.
• A 5-year average of -$105.4 million and a median of $42.9 million in 2025 frame the typical range for Net Cash Flow.
• The sharpest annual moves came in 2022 and 2025: Net Cash Flow tumbled 344.3% in 2022, then soared 137.14% in 2025.
• A 5-year view of Net Cash Flow shows it stood at -$167.0 million in 2022, then surged by 120.83% to $34.8 million in 2023, then surged by 104.99% to $71.3 million in 2024, then decreased by 24.19% to $54.1 million in 2025, then sank by 172.83% to -$39.4 million in 2026.
• Business Quant data shows LKFT's Net Cash Flow at -$39.4 million in Q1 2026, $54.1 million in Q4 2025, and $64.9 million in Q3 2025.